Eton Pharmaceuticals (ETON) Cash & Equivalents (2017 - 2025)

Eton Pharmaceuticals has disclosed Cash & Equivalents across 9 years of filings, most recently posting $25.9 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $25.9 million, up 73.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $25.9 million (up 73.69% YoY), and the FY2025 annual result was $25.9 million, up 73.69% from the prior year.
• Cash & Equivalents came in at $25.9 million for Q4 2025 at Eton Pharmaceuticals, down from $37.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $37.1 million in Q3 2025 to a low of $13.4 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $19.0 million (2024), against an average of $20.3 million.
• Across the five-year window, Cash & Equivalents surged 209.72% in 2021 and plunged 41.09% in 2022, its largest moves.
• Eton Pharmaceuticals' Cash & Equivalents stood at $14.4 million in 2021, then grew by 13.18% to $16.3 million in 2022, then surged by 31.17% to $21.4 million in 2023, then slumped by 30.17% to $14.9 million in 2024, then jumped by 73.69% to $25.9 million in 2025.
• The last three Cash & Equivalents figures came in at $25.9 million (Q4 2025), $37.1 million (Q3 2025), and $25.4 million (Q2 2025), per Business Quant data.